Restore Medical, Inc. (NASDAQ:REST), developer of the innovative
Pillar� Palatal Implant System, today announced financial results
for the three and 12 months ended December 31, 2007, and estimated
net sales for the first quarter of 2008. The Pillar Palatal Implant
System is a proven and effective in-office treatment for people
suffering from snoring and mild to moderate obstructive sleep apnea
(OSA) that improves the lifestyles of patients and their bed
partners by helping them to sleep better, feel better and live
better. Net sales for the fourth quarter of 2007 were $788,000,
compared with net sales of $1.1 million for the fourth quarter of
2006. U.S. sales were $764,000 for the fourth quarter of 2007,
compared with $941,000 in the prior year quarter, and international
sales were $24,000 in the fourth quarter of 2007, compared with
$165,000 for the fourth quarter of 2006. Net sales for the full
2007 year were $4.1 million, compared with net sales of $5.9
million in 2006. U.S. sales were $3.7 million in 2007, compared
with $4.6 million in 2006, and international sales were $419,000
for 2007, compared with $1.3 million in 2006. �Our fourth quarter
sales results reflect five primary factors,� said Bob Paulson,
President and CEO. �During the quarter we had five open sales
territories, representing 25% of our sales force and the majority
of the decrease in U.S. sales compared with the prior-year quarter.
Over the course of 2007, we essentially replaced our entire current
U.S. sales force as part of our consultative sleep practice
development strategy, and we intentionally did not fill these five
open sales territories in the fourth quarter while we continued to
closely monitor and evaluate the progress of our new initiatives
regionally across the country. Although overall market conditions
impacted our U.S. business in the quarter similar to other
lifestyle medicine markets, our quarterly results also reflect our
ongoing strategic shift to emphasize repeat business from existing
customers over attracting new ENT customers. Lastly, the decline in
international sales was expected and is consistent with our
previously announced decision to focus on our U.S. business.�
Paulson added, �The most important objectives of the consultative
sleep practice development sales and marketing programs we
introduced in the U.S. during 2007 were to increase the number of
Pillar Procedures performed and reorders from select customers in
each territory who are committed to treating sleep patients and
growing their sleep practices, as opposed to broadly seeking new
customers who merely expressed an interest in sleep. Although sales
declined in the fourth quarter for the reasons discussed above, our
focused consultative approach demonstrated meaningful results in
the fourth quarter with the number of reorders from U.S. customers
increasing by 24% over the fourth quarter of 2006.� Gross profit
for the fourth quarter of 2007 was $566,000 or 72% of net sales,
compared with gross profit of $697,000 or 63% of net sales for the
fourth quarter of 2006. Gross profit for 2007 was $3.1 million or
75% of net sales, compared with gross profit of $4.2 million or 71%
of net sales for 2006. This gross margin improvement in 2007 was
due to lower production costs and increased manufacturing
efficiencies. The reported net loss attributable to common
stockholders in the fourth quarter of 2007 was $3.1 million, or
$0.19 per share, compared with a net loss of $4.1 million, or $0.26
per share, in the fourth quarter of 2006. The reported net loss
attributable to common stockholders in 2007 was $13.5 million, or
$0.84 per share, compared with a net loss of $33.8 million, or
$3.26 per share, for 2006. Restore Medical had cash, cash
equivalents and short-term investments of $10.2 million as of
December 31, 2007, compared with $23.8 million as of December 31,
2006. As a result of the fact that the Company will need to raise
additional capital to fund future operations beyond mid 2008, the
Audit Report issued by the Company�s Independent Registered Public
Accountants that is included in Company�s Annual Report on Form
10-K for the year ended December 31, 2007, states in part, that the
Company currently does not have sufficient capital resources to
fund future operations, which raises substantial doubt about the
Company�s ability to continue as a going concern. NASDAQ�s
marketplace rules require NASDAQ-listed companies to publicly
announce the receipt of an audit opinion containing a going concern
qualification. The Company anticipated this going concern opinion
and has been actively exploring various equity and strategic
financing alternatives to ensure the Company has sufficient capital
to fund operations. Estimated First Quarter 2008 Net Sales Restore
Medical estimates that net sales for the first quarter of 2008 will
be more than $1.2 million. U.S. sales are estimated to be more than
$1.0 million, up slightly from the first quarter of 2007 and up
more than 30% sequentially over the fourth quarter of 2007.
International sales are estimated to be approximately $200,000, a
significant increase over both the first and fourth quarters of
2007. Mr. Paulson commented, �We believe the revenue growth we have
seen in the first quarter of 2008 reflects building momentum with
our key customers as our sales and marketing strategies gain
traction in the dynamic and rapidly evolving sleep market, despite
the fact we had five open sales territories in the U.S. We are
encouraged that throughout 2007 and early 2008 we have seen a
number of positive developments, not only in our business, but also
in the evolution of the sizeable and growing sleep market. In
February, the first peer-reviewed Level 1 randomized placebo study
validating use of the Pillar Procedure to effectively treat both
mild to moderate OSA and chronic snoring was published, and two
weeks ago, The Centers for Medicare and Medicaid Services
implemented a national coverage determination to reimburse home
sleep studies, which has long been advocated by the American
Academy of Otolaryngology. Chronic snoring and OSA are health,
quality-of-life and lifestyle issues for millions of people.
Increasing numbers of people, and their doctors, are seeking
alternatives to traditional sleep therapies and surgical
procedures, and we expect the Pillar Procedure will be an
increasingly important treatment option in the continuum of care
for obstructive sleep disorders.� Conference Call and Webcast
Information Management will be hosting an investment-community
conference call today beginning at 5:00 p.m. Eastern time (4:00
p.m. CDT) to discuss these financial results, to provide a business
update and to answer questions. To participate in the live call by
telephone, please dial (800) 642-1381 from the U.S., or (706)
634-7417 from outside the U.S. A telephone replay will be available
from 7:00 p.m. Eastern time on March 27, 2008 through 11:59 p.m.
Eastern time on March 29, 2008 by dialing (800) 642-1687 (domestic)
or (706) 645-9291 (international). The conference ID is 36602874.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Investor Relations section of
Restore Medical�s web site at www.restoremedical.com. A replay will
be available on the web site. About Restore Medical and the Pillar
Procedure Restore Medical develops, manufactures and markets
innovative medical devices to treat sleep-disordered breathing. The
Company's proprietary Pillar� Palatal Implant System is the only
implantable palatal device to treat snoring and mild to moderate
obstructive sleep apnea to be approved by the U.S. Food and Drug
Administration and by Health Canada, and to have received the CE
Mark for sale in the European Union. The Pillar Palatal Implant
System is sold throughout the U.S. and Canada, and in various
countries in Asia Pacific, Europe, South America and the Middle
East. For more information about Restore Medical, the Pillar
Procedure and physicians who offer the Pillar Procedure in the
U.S., visit the company�s website at www.restoremedical.com or
www.pillarprocedure.com. Forward-Looking Statements Except for
historical information, this press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements included
in this press release that address activities, events or
developments that Restore Medical expects, believes or anticipates
will or may occur in the future, including, particularly,
statements about its available cash and financing plans, expected
net sales, sales force hires, future financial and operating
results and financial guidance, are forward-looking statements. All
forward-looking statements are based on assumptions made by Restore
Medical�s management based on its experience and perception of
historical trends, current conditions, expected future developments
and other factors it believes are appropriate in the circumstances.
Such statements are subject to a number of assumptions, risks and
uncertainties, many of which are beyond the Company�s control, and
which could cause actual results or events to differ materially
from those expressed in such forward-looking statements. Factors
that could cause or contribute to such differences include, but are
not limited to, available cash resources, market demand and
acceptance of the Company�s products, competitive factors, pricing
and third-party reimbursement for the Company�s products, expansion
and rate of success of the Company�s sales force, completion and
results of clinical studies, ongoing regulatory compliance, success
of new product development, general economic conditions and
seasonal trends, and other risks and factors that are discussed in
documents filed by Restore Medical with the Securities and Exchange
Commission from time to time, including its Annual Report on Form
10-K for the year ended December 31, 2007. Forward-looking
statements represent the judgment of the Company's management as of
the date of this release, and Restore Medical disclaims any intent
or obligation to update any forward-looking statements. RESTORE
MEDICAL, INC. Balance Sheets (In thousands, except per share
amounts) � December 31, � December 31, Assets 2007 2006 Current
assets: Cash and cash equivalents $ 3,964 $ 11,377 Short-term
investments 6,285 12,463 Accounts receivable, net of allowance for
doubtful accounts of $21 and $86, respectively 604 1,262
Related-party receivables 16 33 Inventories 785 598 Prepaid
expenses 141 237 Other current assets � 13 � � 10 � Total current
assets 11,808 25,980 Machinery and equipment, net 487 539 Deferred
debt issuance costs, net of accumulated amortization of $251 and
$128, respectively � 123 � � 246 � Total assets $ 12,418 � $ 26,765
� � Liabilities and Stockholders� Equity Current liabilities:
Accounts payable $ 275 $ 670 Accrued expenses 344 939 Accrued
payroll and related expense 616 519 Current portion of long-term
debt, net of debt discount of $37 and $37, respectively � 2,806 � �
2,192 � Total current liabilities 4,041 4,320 Long-term debt, net
of debt discount of $0 and $37, respectively 143 2,863 Other
long-term liabilities � 16 � � 14 � Total liabilities � 4,200 � �
7,197 � � Commitments and contingencies � Stockholders� equity:
Common stock $0.01 par value: 50,000,000 shares authorized; issued
and outstanding 15,731,094 and 15,534,244 shares, respectively 157
155 Additional paid-in capital 94,228 92,772 Deferred stock-based
compensation (690 ) (1,395 ) Accumulated deficit � (85,477 ) �
(71,964 ) Total stockholders� equity � 8,218 � � 19,568 � Total
liabilities and stockholders� equity $ 12,418 � $ 26,765 � RESTORE
MEDICAL, INC. Statements of Operations (In thousands, except per
share amounts) Three months ended � Year ended December 31,
December 31, 2007 � 2006 2007 � 2006 (unaudited) Net sales $ 788 $
1,106 $ 4,101 $ 5,886 Cost of sales (1) � 222 � � 409 � � 1,035 � �
1,695 � Gross margin � 566 � � 697 � � 3,066 � � 4,191 � Operating
expenses: Research and development (1) 711 747 3,277 3,007 General
and administrative (1) 954 1,142 4,598 4,960 Sales and marketing
(1) � 1,988 � � 3,061 � � 8,867 � � 10,022 � Total operating
expenses � 3,653 � � 4,950 � � 16,742 � � 17,989 � Loss from
operations � (3,087 ) � (4,253 ) � (13,676 ) � (13,798 ) Other
income (expense): Interest income 146 340 852 952 Interest expense
(148 ) (217 ) (689 ) (734 ) Preferred stock warrant gain (loss) - -
- 500 Other, net � - � � 39 � � - � � 50 � Total other income
(expense) � (2 ) � 162 � � 163 � � 768 � Net loss (3,089 ) (4,091 )
(13,513 ) (13,030 ) � Deemed dividend from revision of preferred
stock conversion price � - � � - � � - � � (20,799 ) Net loss
attributable to common stockholders $ (3,089 ) $ (4,091 ) $ (13,513
) $ (33,829 ) � Basic and diluted net loss per common share before
deemed dividend from revision of preferred stock conversion price $
(0.19 ) $ (0.26 ) $ (0.84 ) $ (1.26 ) Effect of deemed dividend
from revision of preferred stock conversion price � - � � - � � - �
� (2.00 ) Basic and diluted net loss per common share $ (0.19 ) $
(0.26 ) $ (0.84 ) $ (3.26 ) � Basic and diluted weighted average
common shares outstanding 16,108,957 15,890,720 16,066,649
10,377,793 � (1) Includes stock-based compensation of: Cost of
sales $ 25 $ 26 $ 103 $ 79 Research and development 79 47 206 148
General and administrative 253 432 1,363 1,415 Sales and marketing
� 59 � � 5 � � 282 � � 211 � $ 416 � $ 510 � $ 1,954 � $ 1,853 �
Restore Medical (MM) (NASDAQ:REST)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Restore Medical (MM) (NASDAQ:REST)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024